E3 PreliminaryModerate confidencePEM not requiredMethods-PaperPeer-reviewedMachine draft
Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA.
Falkenberg, Virginia R, Whistler, Toni, Murray, Janna' R et al. · BMC research notes · 2011 · DOI
Quick Summary
Researchers studying ME/CFS need reliable ways to measure gene activity in blood samples. This study found that a gene called PGK1 is a stable and reliable 'reference point' for comparing gene measurements across different blood collection methods and sample types. Using a single stable reference gene like PGK1 makes it easier for scientists to get accurate, comparable results when searching for blood-based biomarkers of ME/CFS.
Why It Matters
Standardized gene expression measurement techniques are essential for identifying and validating ME/CFS biomarkers. This work establishes methodological consistency that allows blood-based gene expression studies to be reliably compared across different laboratories and collection protocols, accelerating biomarker discovery and validation in ME/CFS research.
Observed Findings
- PGK1 was identified as an optimal and stable reference gene for normalization in both whole blood RNA and PBMC RNA samples.
- RPLP0 was identified as an optimal supplementary reference gene specifically for PBMC RNA analysis.
- PPIB was identified as an optimal supplementary reference gene specifically for whole blood RNA analysis.
- A single stable reference gene is sufficient for accurate normalization in qRT-PCR studies, rather than requiring multiple genes.
- Use of optimal reference genes improves the ability to compare gene expression results between whole blood and PBMC samples and across different collection methods.
Inferred Conclusions
- PGK1 is a reliable reference gene for quantitative gene expression studies in blood samples relevant to ME/CFS research.
- Optimal reference gene selection improves standardization and comparability of gene expression results across different collection and processing methods.
- Large-scale molecular epidemiologic studies using blood RNA will benefit from these standardized normalization approaches in biomarker discovery efforts.
Remaining Questions
- How do these reference genes perform in ME/CFS patient samples specifically compared to healthy controls?
What This Study Does Not Prove
This study does not identify any disease biomarkers or genes associated with ME/CFS pathology itself—it only establishes technical standards for measuring gene expression reliably. It does not prove that any particular gene is dysregulated in ME/CFS patients, nor does it validate biomarker utility in diagnosis or prognosis.
Tags
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- DOI
- 10.1186/1756-0500-4-324
- PMID
- 21896205
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →